Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Griggs, R. C.
Right arrow Articles by McQuillen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griggs, R. C.
Right arrow Articles by McQuillen, J.
NEUROLOGY 1978;28:1259
© 1978 American Academy of Neurology

Hereditary paroxysmal ataxia

Response to acetazolamide

Robert C. Griggs, M.D., Richard T. Moxley, III, M.D., Richard A. Lafrance, M.D. and James McQuillen, M.D.

Departments of Neurology, Medicine, and Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York (Drs. Griggs, Moxley, and Lafrance); and the Department of Pathology, University of Vermont, Burlington (Dr. McQuillen).

From early childhood, eight patients in a kindred had paroxysmal bouts of ataxia, dysarthria, and nystagmus. The disorder was inherited as an autosomal dominant. Attacks occurred weekly and lasted 1 to 6 hours; there were slight cerebellar signs between attacks. Although the etiology was not determined, a serendipitous trial of acetazolamide completely abolished attacks, and all patients have remained free of attacks for as long as 5 years.

Reprint requests should be addressed to Dr. Robert C. Griggs, Department of Neurology, 601 Elmwood Avenue, Rochester, NY 14642.

Supported in part by the Muscular Dystrophy Association and USPHS Grant No. RR 00044 from the Division of Research Resources of the National Institutes of Health.

This article was presented in part at the twenty-ninth meeting of the American Academy of Neurology, Atlanta, Georgia, April 29, 1977.

Accepted for publication January 4, 1978.




This article has been cited by other articles:


Home page
BrainHome page
J.C. Jen, T.D. Graves, E.J. Hess, M.G. Hanna, R.C. Griggs, R.W. Baloh, and the CINCH investigators
Primary episodic ataxias: diagnosis, pathogenesis and treatment
Brain, October 1, 2007; 130(10): 2484 - 2493.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
L. H. Eunson, T. D. Graves, and M. G. Hanna
New calcium channel mutations predict aberrant RNA splicing in episodic ataxia
Neurology, July 26, 2005; 65(2): 308 - 310.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
S. D. Spacey, L. A. Materek, B. I. Szczygielski, and T. D. Bird
Two Novel CACNA1A Gene Mutations Associated With Episodic Ataxia Type 2 and Interictal Dystonia
Arch Neurol, February 1, 2005; 62(2): 314 - 316.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
P. Imbrici, S. L. Jaffe, L. H. Eunson, N. P. Davies, C. Herd, R. Robertson, D. M. Kullmann, and M. G. Hanna
Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia
Brain, December 1, 2004; 127(12): 2682 - 2692.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
July 27 Highlight and Commentary
Neurology, July 27, 2004; 63(2): 197 - 197.
[Full Text] [PDF]


Home page
NeurologyHome page
M. Strupp, R. Kalla, M. Dichgans, T. Freilinger, S. Glasauer, and T. Brandt
Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine
Neurology, May 11, 2004; 62(9): 1623 - 1625.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
R. J. Leigh
Potassium channels, the cerebellum, and treatment for downbeat nystagmus
Neurology, July 22, 2003; 61(2): 158 - 159.
[Full Text] [PDF]


Home page
Arch NeurolHome page
A. H. Koeppen
Familial Hemiplegic Migraine
Arch Neurol, May 1, 2003; 60(5): 663 - 664.
[Full Text] [PDF]


Home page
BrainHome page
D. M. Kullmann
The neuronal channelopathies
Brain, June 1, 2002; 125(6): 1177 - 1195.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
J. Jen and D. H. Geschwind
Ataxia and Calcium Channels: What a Headache!
Arch Neurol, February 1, 2001; 58(2): 179 - 180.
[Full Text] [PDF]


Home page
Arch NeurolHome page
C. Denier, A. Ducros, A. Durr, B. Eymard, B. Chassande, and E. Tournier-Lasserve
Missense CACNA1A Mutation Causing Episodic Ataxia Type 2
Arch Neurol, February 1, 2001; 58(2): 292 - 295.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. Jen, Q. Yue, S. F. Nelson, H. Yu, M. Litt, J. Nutt, and R. W. Baloh
A novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia
Neurology, July 1, 1999; 53(1): 34 - 34.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. Battistini, S. Stenirri, M. Piatti, C. Gelfi, P. G. Righetti, R. Rocchi, F. Giannini, N. Battistini, G. C. Guazzi, M. Ferrari, et al.
A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia
Neurology, July 1, 1999; 53(1): 38 - 38.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. Denier, A. Ducros, K. Vahedi, A. Joutel, P. Thierry, A. Ritz, G. Castelnovo, T. Deonna, P. Gerard, J. L. Devoize, et al.
High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2
Neurology, June 1, 1999; 52(9): 1816 - 1816.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
J. C Jen, Q. Yue, J. Karrim, S. F Nelson, and R. W Baloh
Spinocerebellar ataxia type 6 with positional vertigo and acetazolamide responsive episodic ataxia
J. Neurol. Neurosurg. Psychiatry, October 1, 1998; 65(4): 565 - 568.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1978 by AAN Enterprises, Inc.